Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
Outline of Final Research Achievements |
In the present study, we found that activated CD4+ T cells secreted p19 and EBI3, and that forced expression of them in cultured cells showed association of them. Moreover, injection of expression vector of EBI3/p19 into mice augmented IL-17 production, and transgenic mice of EBI3/p19 showed increased resistance to the development of autoimmune hepatitis possibly due to enhanced production of IL-22. Taken together, these results suggested that EBI3/p19 may be a novel functional heterodimeric molecule.
|